Phagepro, Inc.

We are committed to using our expertise in microbiology, global health, and social entrepreneurship to grow our team by cultivating relationships with critical partners that will help us build the infrastructure for introducing a new modality of prevention and treatment for bacterial diseases. Our team is innovative in our science and vigilant in our R&D approach to designing products for low- and middle-income countries (LMIC). Interwoven into all levels of the company are efforts to provide more leadership opportunities to women and people of color. We believe strongly that as a global health startup, all voices must be heard to be successful. Our company is a discovery-driven venture spun out of the Camilli Lab at Tufts University, where Professor Andrew Camilli has studied cholera for over 20 years.